Navigation Links
ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007
Date:3/31/2008

for the funding and continued development of the SonoLysis technology; the Company's efforts to extend the expiration dating on future lots of urokinase; the Company's belief that its labeled inventory will be sufficient to meet market demand through September 2009; Microbix's ability to transfer the urokinase manufacturing process; the Company expect that it will close the transaction with Abbott in the second quarter of 2008; and the Company's belief that it will have sufficient cash resources for at least the next 12 months. These statements are based on management's current expectations and beliefs and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward- looking statements. A more complete description of these risks and the event that may cause such events not to occur can be found in the Company's filings with the Securities and Exchange Commission. All information in this press release is as of March 31, 2008, and the Company undertakes no duty to update this information.
. .

ImaRx Therapeutics, Inc.

Consolidated Statements of Operations

(in thousands except share and per share data)

Three Months Ended Year Ended

December 31 December 31

2006 2007 2006 2007

(unaudited)

Revenues:

Product sales, net $226 $2,472 $480 $7,841

Research and development 481 178 848 519

Total operating revenue 707 2,650 1,328 8,360

Costs and expenses:

Cost of product sales 204 989 204 3,518

Research and development 2,589 2,033 9,067 7,424

<
'/>"/>
SOURCE ImaRx Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. ImaRx Therapeutics Receives Urokinase Lot Release Approval With Extended Expiration Dating
2. ImaRx to Report Corporate Updates and 4Q07 Financial Results
3. ImaRx Reschedules Release of Corporate Updates and Fourth Quarter and Full Year 2007 Financial Results
4. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
5. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
6. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
7. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
8. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
9. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
10. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
11. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Sept. 18, 2014 Research and ... "Global N-acetylcysteine Industry Report 2014" report ... N-acetylcysteine Industry Report 2014 is a professional and ... global N-acetylcysteine industry. The report provides ... classifications, applications and industry chain structure. The N-acetylcysteine ...
(Date:9/18/2014)... 2014 Leatherwood Plastics has selected ... to stay competitive in the semiconductor, clean room ... ultimately impact product quality and productivity, according to ... Established in 1980 in Lewisville, TX, Leatherwood ... have left the business. Much of Leatherwood’s equipment ...
(Date:9/18/2014)...  Neogen Corporation (Nasdaq: NEOG ) announced ... with Merck Animal Health to market Neogen,s Igenity ® ... Dairy Heifer Program consists of genomic tests that offer ... of replacement dairy heifers. The genomic tests can be ... an excellent tool in the decision-making process for breeding ...
(Date:9/18/2014)... , Sept. 18, 2014   Sigma-Aldrich ... today it has entered into a new gene ... Medical School,s Vector Core. Under the partnership, Sigma-Aldrich ... technology, experimental design consultation, and dedicated gene editing ... accelerate gene editing-based research at the U-M Medical ...
Breaking Biology Technology:Global N-acetylcysteine Industry Report 2014 2Leatherwood Plastics Selects Vycom’s Flametec PVC-C Material to Stay Competitive in Semiconductor and Lab Equipment Industries 2Merck Animal Health to market Neogen's dairy genomic program 2Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 2Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 3Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 4
... scientist in the Center for Nano Science and Technology ... example of a nanotechnology-related safety and ethics problem that ... which involves science and engineering down at billionths-of-a-meter scales, ... the application of that technology to everyday experience has ...
... 2012, GeneLink,s common stock began trading under the symbol "GNLKE" ... as it is due to the late filing of the ... December 31, 2011.  The Company anticipates that all work should ... the period ended December 31, 2011 is anticipated to be ...
... Mass., April 27, 2012  X-BODY BioSciences, Inc., a developer ... novel methods of selecting for antibodies against targets on ... Summit (PEGS) and the associated Biologics Partnering Forum being ... Richard Wagner, Ph.D., Co-Founder and Executive ...
Cached Biology Technology:Notre Dame paper examines nanotechnology-related safety and ethics problem 2Notre Dame paper examines nanotechnology-related safety and ethics problem 3GeneLink Anticipates Completion of Audit 2X-BODY BioSciences to Present Novel Methods of Selecting for Antibodies Against Targets on Live Cells at CHI's Protein Engineering Summit 2
(Date:9/18/2014)... entire lives nestling in the protective tentacles of host ... sometimes travel hundreds of kilometres across the open ocean. ... has been predicted, this is the first time that ... has been observed. , Dr Steve Simpson, Senior Lecturer ... of Exeter, and colleagues from the Australian Research Council ...
(Date:9/17/2014)... UCLA atmospheric scientists were instrumental in the creation of ... tool to classify the fire threat potential of the ... a spark into an inferno. The index was introduced ... with UCLA and San Diego Gas and Electric. , ... to "extreme" that will be used to help fire ...
(Date:9/17/2014)... student have designed a device based on a shorebird,s ... dew., The device could provide water in drought-stricken areas ... Luo, professor in the Mechanical & Aerospace Engineering Department, ... of Engineering department, published "Bioinspired Plate-Based Fog Collectors" in ... Applied Materials & Interfaces journal. ...
Breaking Biology News(10 mins):Expedition finds Nemo can travel great distances to connect populations 2Expedition finds Nemo can travel great distances to connect populations 3UCLA scientists play key role in developing new Santa Ana Wildfire Threat Index 2Shorebird's beak inspires UT Arlington research on water collection 2
... genetic mutations, stunted growth and declining fertility among small ... Sydney Harbour, new research shows. The finding adds ... Sydney Harbour are a deadly diet for many sea ... Science of the Total Environment , reveal genetic ...
... signs of fetal alcohol syndrome are slight but classic: facial malformations ... and a short nose. Researchers want to know if those ... takes during what point in development to cause these and other ... glasses of wine over an hour in the first few weeks ...
... Institute and The Children,s Hospital in Denver have conducted the ... of a rare genetic disorder in which males have two ... of each. The study, published in the June 15, 2008, ... A, also offers treatment recommendations for men and boys ...
Cached Biology News:Heavy metal link to mutations, low growth and fertility among crustaceans in Sydney Harbor tributary 2Alcohol consumption can cause too much cell death, fetal abnormalities 2UC Davis researchers define characteristics, treatment options for XXYY syndrome 2UC Davis researchers define characteristics, treatment options for XXYY syndrome 3
... Power Supply is designed specifically ... extensive programming capabilities including eight ... for you to set to ... intuitive PowerEase interface is faster ...
Assay Kit formatted for flow cytometric detection of levels of phosphorylated histone H2A.X....
... Z-Competent E. coli Transformation Buffer Set are ... E. coli cells for simple and highly ... eliminates the requirement for heat shocking and ... be performed by adding DNA to Z-Competent ...
Request Info...
Biology Products: